ProShares UltraShort NASDAQ Biotechnology
9 hedge funds and large institutions have $12.7M invested in ProShares UltraShort NASDAQ Biotechnology in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 5 closing their positions.
212% more call options, than puts
Call options by funds: $5.81M | Put options by funds: $1.86M
164% more capital invested
Capital invested by funds: $4.82M → $12.7M (+$7.91M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
29% more funds holding
Funds holding: 7 → 9 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$10M |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$1.38M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.29M |
| 4 |
ST
Spot Trading
Chicago,
Illinois
|
+$393K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$891K |
| 2 |
CANY
Caxton Associates (New York)
New York
|
-$891K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$455K |
| 4 |
SM
Southport Management
Wilson,
Wyoming
|
-$267K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCMT
1
Highland Capital Management (Texas)
Dallas,
Texas
| $8.3M | +$10M | +14,569 | New |
|
|
HVC
2
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| $2.85M | +$1.29M | +1,875 | +60% |
|
|
3
Zurich Cantonal Bank
Zurich,
Switzerland
| $1.14M | +$1.38M | +2,000 | New |
|
|
ST
4
Spot Trading
Chicago,
Illinois
| $325K | +$393K | +571 | New |
|
|
U
5
UBS
Zurich,
Switzerland
| $30K | +$5.51K | +8 | +18% |
|
|
FTUS
6
Flow Traders U.S.
New York
| $30K | +$36.5K | +53 | New |
|
7
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $28K | +$34.4K | +50 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $13K | +$16.5K | +24 | New |
|
9
Morgan Stanley
New York
| $12K | +$14.5K | +21 | New |
|
|
BGA
10
Belmont Global Advisors
Dallas,
Texas
| – | -$891K | -1,250 | Closed |
|
|
CANY
11
Caxton Associates (New York)
New York
| – | -$891K | -1,250 | Closed |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$455K | -660 | Closed |
|
|
SM
13
Southport Management
Wilson,
Wyoming
| – | -$267K | -375 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$36K | -50 | Closed |
|
BIS Hedge Fund Activity: Q2 2014 in Review
9 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2014, worth a combined $12.7M — up 164% from $4.82M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIS positions and 5 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Highland Capital Management (Texas), opening a new position worth an estimated $10M. The largest seller was Belmont Global Advisors, exiting entirely with an estimated $891K sold.
- 9 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2014, up from 7 in Q1 2014.
- Funds reported $12.7M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2014, up 164% quarter-over-quarter.
- 7 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2014 and 5 closed out, a net change of +2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2014 was Highland Capital Management (Texas), an estimated $10M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2014 was Belmont Global Advisors, an estimated $891K sold.
Based on aggregated 13F filings for Q2 2014.